Other Clinical Trial - Financial Distress in Advanced Cancer Patients

Status Active, not recruiting

Clinical Trial Summary

This trial studies the severity of financial distress in advanced cancer patients. The cost of cancer care can often be very expensive. Financial distress from the burdens of high costs and debt may interfere with a patient's physical symptoms and quality of life.

Clinical Trial Description

PRIMARY OBJECTIVES: I. To determine the frequency of high financial distress in advanced cancer patients. SECONDARY OBJECTIVES: I. To determine the association between high financial distress with clinical and demographic characteristics in advanced cancer patients. II. To determine the correlation between In Charge Financial Distress/ Financial Well-Being Scale (IFDFW) and other financial distress instruments such as Comprehensive Score for Financial Toxicity-Functional Assessment of Chronic Illness Therapy (COST-FACIT) and Edmonton Symptom Assessment Scale- Financial Distress (ESAS-FS). III. To determine the association between high financial distress with patient symptoms in ESAS-FS and quality of life assessed by the Functional Assessment of Cancer Therapy - General (FACT-G). OUTLINE: Patients complete questionnaires about financial state and quality of life over 15 minutes. Patients' medical chart is also reviewed. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04053517
Study type	Observational
Source	M.D. Anderson Cancer Center
Contact
Status	Active, not recruiting
Phase
Start date	July 2, 2019
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03671226` - Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their Caregivers Who Are Seen in the Outpatient Supportive/Palliative Care Center	N/A
Recruiting	`NCT05048160` - A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm	Phase 1/Phase 2
Active, not recruiting	`NCT03287492` - RCT of QPS vs General Information Sheet	N/A
Recruiting	`NCT01549067` - The Real Clinical Background of Advanced Colorectal Cancer Treatment Situation Survey	N/A
Recruiting	`NCT04119037` - Cordotomy in Reducing Pain in Patients With Advanced Cancer	N/A
Recruiting	`NCT04067336` - First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia	Phase 1/Phase 2
Recruiting	`NCT04585750` - The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)	Phase 1/Phase 2
Completed	`NCT02823652` - Pre-Test Genetic Education and Remote Genetic Counseling in Communicating Tumor Profiling Results to Patients With Advanced Cancer	N/A
Completed	`NCT00244972` - Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer	Phase 1
Active, not recruiting	`NCT01582191` - Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer	Phase 1
Active, not recruiting	`NCT03856060` - Videos and Questionnaires in Assessing Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits	N/A
Completed	`NCT04186884` - Caregiver Burden, Quality of Life, and Symptom Distress at Different Palliative Cancer Care Settings
Completed	`NCT02583269` - Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery	Phase 1
Withdrawn	`NCT03868423` - Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers	Phase 2
Terminated	`NCT02940223` - Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer	Phase 2
Active, not recruiting	`NCT01552434` - Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease	Phase 1
Active, not recruiting	`NCT03021486` - Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer	Phase 2/Phase 3
Recruiting	`NCT03203525` - Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer	Phase 1
Completed	`NCT01624766` - Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers	Phase 1
Recruiting	`NCT05985278` - Clinical Application of Lutetium [177Lu]-Catalase in Tumor Radionuclide Therapy	Early Phase 1